Description:

Positive lumpectomy margins are associated with an increased risk for ipsilateral tumor recurrence and necessitate additional procedures to achieve acceptable margins. Re-excision rates are higher in patients with ductal carcinoma in situ (DCIS) versus those with invasive carcinoma. The purpose of this program is to lead a discussion on the clinicopathologic characteristics, surgical techniques, and other outcomes associated with re-excision over time following primary breast conserving surgery.

Faculty:

• Freya R. Schnabel, MD
  Professor, Department of Surgery at NYU Grossman School of Medicine, Director of Breast Surgery NYU Langone

For More Information:

Contact Nancy King at nking@dilon.com

Moderator:

• Susan Boolbol, MD

Panelists:

• Brigid Killelea, MD, FACS
• Michael Alvarado, MD
• Anne Peled, MD
• Lucy De La Cruz, MD

Description:

Not all seeds and tracers are created equal… join us as we take a deep-dive in to the technologies currently available for seed localization and axillary staging, alongside a world-class panel of breast surgical oncologists, with years of collective experience across all available seed localization devices on the market. The great localization debates will tackle everything from seed reliability to MRI visibility, metal instruments, accuracy of measurement, clinical efficacy, and much more.

That’s followed by the world-first, in-person launch of the next generation Sentimag® system and new Magseed® markers - built by Endomag, designed by you. Taking on board feedback from thousands of physicians worldwide, see how the new system has built on the strengths that have made Sentimag® so widely adopted, plus added an abundance of new advanced features.

Description:

PREVENT, the largest randomized clinical trial to assess lymphedema prevention, met its primary endpoint. Join our panel of experts as they debate the recently published results and implications for the future of breast cancer care. Topics covered will include the importance of early lymphedema detection and intervention, supporting clinical evidence, and real-world experience with clinical implementation. Discover how providing your patients with a lymphedema prevention program provides optimal patient care and can positively impact your practice.

Moderated By:

• Dr. Pat Whitworth
  Director
  Nashville Breast Center

Faculty:

• Dr. Beth DuPree
  Breast Surgeon
• Dr. Manpreet Kohli
  Breast Surgeon
  Breast Program Director Monmouth Medical Center
• Dr. Chirag Shah
  Co-Director Comprehensive Breast Program
  Director of Breast Cancer Radiation Oncology and Director of Clinical Research, Department of Radiation Oncology, Cleveland Clinic

Educational Objectives:

• Understand the latest evidence from the PREVENT trial
• Discover the benefits of identifying and treating lymphedema at the subclinical stage
• Learn the best practices and economics for implementing a lymphedema prevention program

Program Objective:

Go beyond wire-free localization into the advanced procedures of TAD and Delayed SLNB. Top experts from around the world review the latest data, the emerging procedures, and share their OR footage of their experiences. Get a glimpse of what’s on the horizon with the next generation Sentimag and dive into the ongoing research.

Agenda:

• The Latest Magseed® TAD Data
  Mr. Peter Barry, London’s Royal Marsden
• Delayed SLNB: The Future of Axillary Staging
  Kandace P. McGuire, MD - VCU
  Melissa Fana, MD - Northwell Health
• Magtrace Efficacy for SLNB Post-NAC
  Dr. Stefan Paepke, MD - Technical University of Munich
• SentiNOT 2.0 Trial and Recruitment Process
  Betsy Bonefas, MD – Baylor College of Medicine

Description:

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to Targeted Axillary Dissection to excellent surgical outcomes. Discover the state-of-the art localization and lymphatic mapping techniques practiced by key opinion leaders from the Cleveland Clinic and University of Colorado. Learn about upcoming SCOUT product enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy.

Panelists:

• Brian Czerniecki, MD, PhD
• Colleen Murphy, MD, FACS
• Anne Peled, MD
• Stephanie Valente, DO, FACS

Description:

In this 30 minute clinical presentation, hear from Dr. Angel Rodriguez on how germline and somatic testing together can inform your surgical decisions, and identify more patients at high risk of cancer recurrence. This presentation will review the portfolio of Natera oncology solutions for germline and somatic testing including Signatera molecular residual disease (MRD) testing and Empower hereditary cancer testing (HCT).

For More Information:

Contact Wing-Kit Chu, Associate Director, Hereditary Cancer Marketing, at wichu@natera.com.

Program Objectives:

Upon completion of this CE activity, participants will be able to:

1. Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer
2. Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing
3. Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials
4. Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment

Description:

Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection.

This PeerView Live Clinical Consults event for in-person and virtual attendees will provide essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy.

Accreditation, Support, and Credit:

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.

Description:

Lumpectomy re-excisions remain a challenge for breast surgeons. Hear from Dr. Beth DuPree, an early OCT user, and Dr. Michele Carpenter, who described OCT as “like having a pathology slide in the OR.”

Speakers:

• Michele Carpenter, MD, FACS
  Breast Surgeon
  Orange, CA
• Beth DuPree, MD, FACS, ABOIM
  Breast Surgeon
  Sedona, AZ

For More Information:

Contact Linda Thomas, lthomas@perimetermed.com, 972‑672‑9700.

Featured Guests:

• Moderator: Dr. Richard Fine, Margaret West Comprehensive Breast Center, Memphis, TN
• Dr. Amelia Tower, Texas Health Breast Specialists, Fort Worth, TX
• Dr. Maryam Elmi, The START Center for Cancer Care, San Antonio, TX

Join us for an educational session on the intraoperative use of Perimeter’s groundbreaking margin visualization technology powered by Optical Coherence Tomography (OCT), bringing clarity to margin status at the point of care.

This presentation will cover:

• Technology behind Perimeter’s S-Series OCT, delivering high-resolution specimen imaging for intraoperative margin visualization
• OCT correlations with pathology
• Workflow for bringing OCT into your OR
• Lumpectomy case reviews, including recognizing suspicious tissues
• Bringing AI* to the operating room and investigational study updates
• Panel discussion and Q&A

*Perimeter is currently conducting a randomized control trial to assess its B-Series OCT imaging platform combined with AI technology on the impact of positive margin rates during breast conservation surgery. Perimeter B-Series OCT with ImgAssist AI is not available for sale in the United States. CAUTION: Investigational Device. Limited by U.S. law to investigational use.

Perimeter’s S-Series OCT is cleared by the FDA and available for sale in the U.S.

Overview:

During this live satellite symposium, a multidisciplinary panel of experts in the management of early-stage HR+/HER2- breast cancer will engage in a case-based discussion regarding the personalization of adjuvant therapy for these patients, particularly those with high-risk disease. Topics will include clinical and molecular factors for risk assessment, recent clinical data with endocrine regimens integrating CDK4/6 inhibitors, and management of adverse events associated with new agents. This program will highlight current best practices and the integration of emerging data into daily practice to optimize outcomes for patients with early-stage HR+/HER2- breast cancer, using a lively tumor-board format with opportunity for audience questions and interaction.

For help or questions please contact: info@gotoper.com.

Description:

Join us for a published data review of the highly anticipated DCISionRT validation results in the randomized SweDCIS patient cohort. Practicing physicians will be discussing implications of this new data and the clinical utility of DCISionRT in minimizing over- and under-treatment of DCIS patients. There will be interactive discussions about meaningful application of DCISionRT into surgical practice and real-world patient case studies regarding oncoplastic surgical planning.

Faculty:

• Anne Peled, MD
  Co-Director, Sutter CPMC Breast Cancer Program
• Karen Barbosa, DO, FACOS
  Breast Surgeon and Oncoplastic Surgeon and Medical Director, TidalHealth Delaware Breast Cancer Program
• Pat Whitworth, MD, FACS
  Breast Surgical Oncology Specialist, Director of the Nashville Breast Center
• Chirag Shah, MD
  Co-Director of the Comprehensive Breast Program, Cleveland Clinic
• Troy Bremer, PhD
  Founder and CSO of PreludeDx

For More Information:

Contact alindsay@preludedx.com, cdunn@preludedx.com

Description:

Please join us for a case-based discussion on innovative solutions that may minimize complications after challenging breast surgery cases. Contact Alexandra Castillo at acastillo8@mmm.com.

Description:

This symposium will feature a case-based discussion of Mammaprint and Blueprint's clinical utility for patients with Early-Stage Breast Cancer. Pat Whitworth, MD, and William Audeh, MD, will discuss real world evidence and published clinical data in the context of patient care. Attendees will participate in an interactive Q&A at the end of the presentation.

Presenter:

• William Audeh, MD
  Chief Medical Officer, Agendia

Discussant:

• James Pellicane, MD
  Director of Breast Oncology, Bon Secours Cancer Institute

For More Information:

Contact Israel Madera at israel.madera@agendia.com.

Description

This webinar will empower you with data demonstrating the utility of Agendia’s assays, MammaPrint® and BluePrint®, for patients with breast cancer. Review the latest data and learn about the real-world impact of MammaPrint and BluePrint. Please join us for an informative, interactive webinar.

Description:

Join us as we discuss how to strengthen the patient and provider journey toward an individualized treatment plan. The CARE Program™ provides an end-to-end solution that can help identify high-risk patients earlier for potential proactive medical management and preventative procedures.

Brochure:

Access PDF

Speakers:

• Anjali Date, MD
  Sheila R. Veloz Breast Center Lead Interpreting Physician
• Mari Shay, BSN, RN
  Sheila R. Veloz Breast Center Manager, Women’s Imaging Services
• Kory Jasperson, MS, CGC
  Director, Clinical Services, Ambry Genetics

Description:

Dr. Gillian Newstead (MD, FACR), Director of Global Breast Imaging at University of Chicago, will be talking about Risk Stratified Breast Screening and discussing the importance of breast density. She will share recommendations from the American College of Radiology and the American Society of Breast Surgeons and highlight the importance of supplemental Breast MRI screening for women with specific high risk factors, including women with dense breast tissue.

For More Information:

Contact Lainey Kasian at lainey.kasian@bayer.com.

Description:

In honor of Breast Cancer Awareness Month, we invite you to join a complimentary webinar led by Linda Han, MD, FACS, PPG, Director of Breast Oncology at the Parkview Cancer Institute, where she will discuss the impact of COVID-19 on breast cancer care. During this hour-long webinar we’ll walk through:

• How to screen safely
• Best practices for following guidelines
• The impact on cancer-related mortality
• And provide a forum for Dr. Han to answer your questions

About the Speaker:

• Linda Han, MD, FACS, PPG
  Director of Breast Oncology
  Parkview Cancer Institute

Dr. Han currently serves as the Director of Breast Oncology at Parkview Cancer Institute and Chief Surgery Quality and Optimization Officer for Parkview Health in Fort Wayne, Indiana. She continues to remain active in surgical education as an adjunct professor of clinical surgery and has received numerous teaching awards for excellence in resident and medical student education.

Description:

Presenting the latest data on seed localization, featuring results from iBRA-NET, the world’s largest multicenter seed localization study with over 1,000 patients and the latest findings for TAD with Magseed® from the University of Texas MD Anderson Cancer Center. This is followed by a roundtable Q&A and an exclusive sneak peek at the new Sentimag® Gen 3 platform. For more information, contact Mathew Stephens (mstephens@endomag.com) or Connor Jipps (cjipps@endomag.com).

Description:

Dr. Christy Russell, Sr. Director of Global Medical Affairs at Exact Sciences, and Dr. Susan Boolbol, System Chief of the Breast Surgical Oncology and Breast Program at Nuvance Health, discuss the utility of neoadjuvant endocrine therapy to de-escalate breast and axillary surgery in HR-positive, HER2-negative breast cancer patients. The presentation will also review data pertaining to biomarkers used to make neoadjuvant treatment decisions, including the Oncotype DX Breast Recurrence Score® test. For more information, contact Thomas Mallick (tmallick@exactsciences.com).

Description:

A Live Hologic Virtual Course featuring Cadaveric Assessment and Surgical Skills Advancement. Each of the three recorded sessions include lecture and case examples presented by renowned faculty, cadaveric demonstration of skills, introduction to technology, interactive panel discussion, and the opportunity to ask questions of the panel.

Brochure:

Access PDF

Topics Include:

• Applied Breast Anatomy
• Aesthetic Scar Placement
• Donut Mammoplasty and Modifications for all quadrants
• Managing Complications in Oncoplastic Breast Surgery
• Multi-Disciplinary Decision Making

Educational Objectives:

• Perform aesthetically state of the art surgeries with optimal outcomes
• Understand how technology can reduce re-excisions, returns to OR, and deliver state of the art treatment in an ever-changing health care climate
• Treat tumors in all quadrants without a plastic surgeon
• Have a strong fundamental understanding of breast anatomy and aesthetics to proceed with other training in Level II procedures
• Identify and spot red flags that would lead to poor outcomes

Criteria for Participation:

Practicing breast or general surgeons who perform breast cases, practicing radiologists and radiation oncologists also welcome. Hologic reserves the right to accept or decline any registration or request for attendance. Attendees are limited to those practicing surgery, radiology, or radiation oncology.

Description:

Join the conversation with breast surgeons and a radiation oncologist as they discuss the role of a BioZorb® marker in a Reconstructive Lumpectomy™ surgery as well as the recent publication of the BioZorb® registry in the Annals of Surgical Oncology. Topics include communication with patients and practicing a multidisciplinary approach to patient care.

Faculty:

• Dr. Cary Kaufman
• Dr. Kiran Devisetty
• Dr. Ashley Richardson
• Dr. Lorraine Tafra

Description:

How can you spare up to 78% of high-risk DCIS patients axillary surgery? Join a panel of surgical experts as they discuss how they’re taking patient care to the next level with tailored axillary management procedures and sparing some patients SLNB.

• Roundtable Discussion
• Procedure Videos
• Downloadable Resources

Description:

Join our Faculty for a one-hour webinar as they take a closer look at the ASBrS Nipple Sparing Registry data. Jay Harness, MD will moderate a panel discussion with Shawna Willey, MD, Beth DuPree, MD and William Scarlett, DO as they review how data insights can drive improvement of care and reduce complications in Nipple Sparing Mastectomies. We encourage audience participation, discussion and questions at the end. Please join us for an informative, interactive webinar.

Brochure:

Access PDF

Objectives:

• Evaluate the Nipple Sparing Mastectomy Registry Data and discuss how the results can be used to influence patient outcomes.
• Review the science behind technologies that can help drive more efficient and effective care.
• Discuss breast reconstruction options, including the considerations for patient selection.
• Understand how to reduce complications using impact of technique, proper incision placements and tumescence in surgery.

Target Audience:

• Breast Surgeons
• General Surgeons
• Plastic Surgeons
• Healthcare Providers

Faculty:

• Dr. Jay Harness
• Dr. Shawna Willey
• Dr. Beth DuPree
• Dr. William Scarlett

Questions:

Contact Kirsten Gonya at kirsten.m.gonya@medtronic.com.

Description:

Join our Faculty, Shawna Willey, MD, William Scarlett, DO, and Jay Harness, MD, for a one-hour virtual event as they take a closer look at Nipple Sparing Mastectomy risks & complications. They will discuss the importance of patient selection, the complication rates associated with various measurements, surgical approaches, and the benefits of the tools and technologies used in NSM. We encourage audience participation, discussion and questions at the end. For more information, contact Kirsten Gonya (kirsten.m.gonya@medtronic.com).

Presentation Highlights:

• Utility for Oncoplastic Approaches
• Targeted Axillary Dissection
• Utility of Access Guide for Small Incisions
• Case Reviews

Description:

Join Advocate Health’s Barry Rosen, MD, and Memorial Healthcare’s Mary Hayes, MD, to learn how they uniquely employed SCOUT Radar Localization throughout the patient care continuum and throughout their systems to achieve streamlined, patient-centered care.

Brochure:

Access PDF

Presentation Highlights:

• Cost and clinical advantages derived from going Wire-Free
• Reducing patient facility visits through localizing with SCOUT at biopsy & data review
• Clinical utility of SCOUT for Mastectomy and Oncoplastic approaches

Speakers:

• Barry Rosen, MD, FACS
  Breast Team Leader, Advocate Healthcare, Chicago, IL
  Managing Partner, Targeted Medical Education (TME)
  Assistant Professor of Surgery Univeristy of Illinois College of Medicine
• Mary K. Hayes, MD
  Former Medical Director and Chief of Women’s Imaging at Memorial Healthcare System and Envision

Description:

SCOUT Radar localization exclusively spans the care continuum from time of biopsy placement to Targeted Axillary Dissection to excellent surgical outcomes. Discover the state-of-the art localization techniques practiced by key opinion leaders from the Cleveland Clinic, Columbia University, University of Colorado, Intermountain Healthcare and the Advocate System.

Description:

The panel will evaluate critical factors in optimizing surgical results and recovery across in- and outpatient settings, including:

• Patient selection and engagement
• Communication, multimodal and culture change
• Integrating experience and techniques from plastic surgery

Moderated by:

• Shawna Willey, MD
  Peterson Chair of Breast Cancer Research
  Inova Schar Cancer Institute
  Inova Fairfax Hospital

Panelists:

• Mark Brzezienski, MD
  University of Tennessee Health Science Center
  Professor of Plastic and Orthopedic Surgery
  Chairman and Program Director Department of Plastic Surgery
• Jeff Gonzales, MD
  Staff Anesthesiologist
  Parker Adventist Hospital
• Stephanie Valente, DO
  Breast Surgeon
  Cleveland Clinic

Questions:

For questions, please contact Erin.Fitzpatrick@pacira.com.

Description:

Join us as we present multiple patient cases using a new FDA-cleared intraoperative specimen imaging technology for real-time margin visualization of excised tissue and shaved margins with surgeons from three prestigious institutions involved in Perimeter’s clinical trials. This webinar provides a deeper dive on Optical Coherence Tomography (OCT) – an established, ultra high-resolution technology used in cardiology, dermatology and ophthalmology – and correlates OCT images to histopathology.

Brochure:

Access PDF

Speakers:

• Nina Tamirisa, MD
  Assistant Professor, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
• Maryam Elmi, MD
  Assistant Professor, Division of Surgical Oncology & Endocrine Surgery, University of Texas Health Science Center, San Antonio, TX
• Stacey Carter, MD, FACS
  Assistant Professor of Surgery, Division of Surgical Oncology, Breast Surgery Section, Baylor College of Medicine, Houston, TX

Contact Information:

For more information, contact Andrew Berkeley at aberkeley@perimetermed.com or sales@perimetermed.com or call 214‑845‑5154.

Description:

Learn more about advancements in intraoperative specimen imaging. Optical Coherence Tomography (OCT), a high-resolution imaging modality commonly used in ophthalmology and cardiology, is ideally suited to visualizing margins during a surgical procedure. This webinar also includes insights into how Artificial Intelligence is moving towards the OR and Specimen Imaging.

Brochure:

Access PDF

Presentation Highlights

• Intraoperative Specimen Imaging and the Role of OCT
• OCT in the Operating Room and Case Reviews
• Applying to AI to OCT Specimen Imaging

Speakers:

• Hank Schmidt, MD, PhD
  Associate Professor of Surgery, Mount Sinai School of Medicine, Dubin Breast Center, Tisch Cancer Institute, New York, NY
• Beth DuPree, MD, FACS, ABOIM
  Medical Director Oncology Service Line Centers of Northern Arizona at Northern Arizona Healthcare, AZ
• Alastair Thompson, BSc (Hons), MBChB, MD, FRCS (Ed)
  Professor and Chief, Section of Breast Surgery, Division of Surgical Oncology, Bayor College of Medicine

Contact Information:

For more information, contact Andrew Berkeley at aberkeley@perimetermed.com.